- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05201001
APX005M in Patients With Recurrent Ovarian Cancer (APX005M)
An Early Phase Randomized Trial of APX005M in BRCAwt Patients With Recurrent Ovarian Cancer
Study Overview
Detailed Description
The rationale for integrating immunotherapy with chemotherapy is based on preclinical studies, which have shown, that chemotherapy induces immunogenic cell death leading to increased recognition of the tumor by the immune system. Carboplatin is shown to inhibit PD-L2 expression, thereby limiting immunosuppression by both dendritic cells and tumor cells. Paclitaxel decreases the percentage of CD4+ and FoxP3+ regulatory T cells (Tregs) and reduces their cytokine production without disrupting the function of its effector counterpart (CD4+ and FoxP3 effector T (Teff) cells). Several trials have shown effect of checkpoint inhibition following chemotherapy and radiotherapy, most notably in the PACIFIC trial in stage III NSCLC [63]. We therefore hypothesize, that the proposed combined therapies will yield improved clinical effect in this patient population.
The hypotheses in this study is, that the CD-40 agonist APX005M with or without radiotherapy, and in combination with platinum-doublet chemotherapy, will provide the necessary immune activation and serve as a basis for increased clinical effect of the combination.
Study Type
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Mansoor R Mirza
- Phone Number: +4551963413
- Email: mansoor@rh.regionh.dk
Study Locations
-
-
Sjaelland
-
Copenhagen, Sjaelland, Denmark, 2100
- NSGO-CTU
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Have signed an Institutional Review Board/Independent Ethics Committee-approved informed consent form prior to any study-specific evaluation.
- Histologically diagnosed epithelial ovarian, fallopian tube or primary peritoneal cancer.
- Radiological or histological confirmation of relapse disease ≥ 6 month after last chemotherapy
- Known BRCAwt
- Have completed at least one line of platinum-containing chemotherapy (maximum three previous lines of therapy are permitted). Earlier PARPi treatment permitted
- Must have measurable or evaluable disease according to RESIST 1.1.
- Baseline biopsy: Tissue biopsy for submission to central laboratory prior to study treatment should be from a newly obtained metastatic biopsy, if there is a lesion suitable for biopsy. If a metastatic biopsy is not feasible, or patient is unwilling to provide new biopsy, archival tissue samples should be submitted. Archival tissue sample from metastatic site is preferred; however, archival tissue sample of primary tumor is acceptable.
- Must consent to undergo mandatory tumor biopsy of at least one metastatic site at baseline and at day 84 ( 7). Biopsy at day 84 ( 7) is only applicable if surgery is not performed. -
Exclusion Criteria:
- Previous immunotherapy (for example anti-PD-1/L1).
- Other malignancy unless curatively treated with no evidence of disease for ≥ 3years, except adequately treated non-melanoma skin cancer, curatively treated in situ cancer of the cervix, ductal carcinoma in situ (DCIS) and stage 1 grade 1 endometrial carcinoma.
- Resting ECG indicating uncontrolled, potentially reversible cardiac conditions, as judged by the investigator (e.g. unstable ischemia, uncontrolled symptomatic arrhythmia, congestive heart failure, QTcF prolongation >500 ms, electrolyte disturbances, etc.), or subjects with congenital long QT syndrome.
- Subjects with myelodysplastic syndrome/acute myeloid leukemia or with features suggestive of MDS/AML. Page 48 af 128 ENGOT-OV64/NSGO-CTU-SOLERO EudraCT: 2020-005990-29 Final Version 1.0, 06. July 2021
- Subjects with symptomatic uncontrolled brain metastases. A scan to confirm the absence of brain metastases is not required. Subjects with spinal cord compression unless considered to have received definitive treatment for this and evidence of clinically stable disease for 28 days.
- Subjects with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of randomization. Subjects who have received acute, low-dose, systemic immunosuppressant medications (e.g., a one-time dose of dexamethasone for nausea) or physiologic replacement doses (i.e. prednisone 5 - 7.5 mg/day) for adrenal insufficiency may be enrolled in the study. Inhaled or topical steroids, and adrenal replacement steroid doses ≤ 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease.
- Prior radiation therapy.
- Planned concomitant therapy with any other anticancer therapy
- Conditions requiring ongoing therapy with antibiotics
- History of any arterial thromboembolic event within 3 months prior to first dose of APX005M
- Active coagulopathy
- Previous allogeneic bone marrow transplant or double umbilical cord blood transplantation
- History of organ transplant
- Major surgery or significant traumatic injury within 4 weeks prior to first dose of study drugs
- Pregnant or breastfeeding women.
- Subjects with a known hypersensitivity to any of the excipients of the product.
Any unresolved toxicity NCI CTCAE Grade ≥ 2 from previous anticancer therapy, except alopecia, vitiligo, and the laboratory values defined in the inclusion criteria
- Subjects with Grade ≥ 2 neuropathy will be evaluated on a case-by-case basis after consultation with the Lead Principal Investigator (PI) of the respective collaborative group
- Subjects with irreversible toxicity not reasonably expected to be exacerbated by treatment with study drugs may be included only after consultation with the Lead PI of the respective collaborative group.
Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease [e.g., colitis or Crohn's disease], diverticulitis [with the exception of diverticulosis], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc]). The following are exceptions to this criterion:
- Subjects with vitiligo or alopecia
- Subjects with hypothyroidism (e.g. following Hashimoto syndrome) stable on hormone replacement Page 49 af 128 ENGOT-OV64/NSGO-CTU-SOLERO EudraCT: 2020-005990-29 Final Version 1.0, 06. July 2021
- Any chronic skin condition that does not require systemic therapy
- Subjects without active disease in the last 5 years may be included, but only after consultation with the Lead PI of the respective collaborative group.
- Subjects with celiac disease controlled by diet alone
- Subjects considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active, uncontrolled infection. Examples include, but are not limited to, uncontrolled symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, recent (within 3 months), uncontrolled major seizure disorder, serious chronic gastrointestinal conditions associated with diarrhea, interstitial lung disease or any psychiatric disorder/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the Subject to give written informed consent.
- Immunocompromised subjects, e.g. subjects who are known to be serologically positive for human immunodeficiency virus (HIV).
Active infection including tuberculosis (clinical evaluation that includes clinical history, physical examination and radiographic findings, and TB testing in line with local practice), hepatitis B (known positive HBV surface antigen (HBsAg)), hepatitis C.
Subjects with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody [anti-HBc] and absence of HBsAg) are eligible. Subjects positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA.
- Receipt of live attenuated vaccine within 30 days prior to the first dose of Investigational Product (IP). Note: Subjects, if enrolled, should not receive live vaccine whilst receiving IP and up to 30 days after the last dose of IP. COVID-19 vaccination must be performed minimum 7 days prior to first dose of APX005M. -
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Standard of Care
Carboplatin AUC = 5, IV day 1 and pegylated liposomal doxorubicin (PLD) 30 mg/m , IV day1 q4 wks Total:6 cycles or until progressive disease or unacceptable toxicity. |
adding immunotherapy with or without radiation therapy to chemotherapy.
Low dose radiation therapy is to sensitise tumour cells to immunotherapy.
Other Names:
|
Experimental: APX005M
Carboplatin AUC = 5, IV day 1 combined with pegylated liposomal doxorubicin (PLD) 30 mg/m , IV day1 q4 wks APX005M 0.3 mg/kg, days 1 & 15 IV q4 wks x concomitant with chemotherapy Total:6 cycles or until progressive disease or unacceptable toxicity. |
adding immunotherapy with or without radiation therapy to chemotherapy.
Low dose radiation therapy is to sensitise tumour cells to immunotherapy.
Other Names:
|
Experimental: APX005M+RT
Carboplatin AUC = 5, IV day 1 combined with pegylated liposomal doxorubicin (PLD) 30 mg/m , IV day1 q4 wks APX005M 0.3 mg/kg, days 1 & 15 IV q4 wks x concomitant with chemotherapy External beam radiation therapy; a dose of 0.5 Gy per fraction, administered as single fractions prior to APX005M administration; days 1 & 15 q4 wks x 6 cycles. Maximum 24 wks of therapy; total dose 6 Gy. Total:6 cycles or until progressive disease or unacceptable toxicity. |
adding immunotherapy with or without radiation therapy to chemotherapy.
Low dose radiation therapy is to sensitise tumour cells to immunotherapy.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Response Rate according to RECIST at 12 weeks of treatment
Time Frame: 18 months
|
To evaluate the preliminary efficacy of APX005M-carboplatin-PLD and APX005M radiotherapycarboplatin-PLD combinations
|
18 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse events
Time Frame: 18 months
|
To evaluate adverse events, safety & feasibility of the two combinations
|
18 months
|
Collaborators and Investigators
Collaborators
Investigators
- Study Chair: Mansoor R Mirza, NSGO-CTU
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Genital Neoplasms, Female
- Endocrine System Diseases
- Ovarian Diseases
- Adnexal Diseases
- Gonadal Disorders
- Endocrine Gland Neoplasms
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Genital Diseases
- Genital Diseases, Female
- Ovarian Neoplasms
- Carcinoma, Ovarian Epithelial
- Antineoplastic Agents
- Carboplatin
Other Study ID Numbers
- ENGOT-OV64/NSGO-CTU-SOLERO
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ovarian Cancer
-
Roswell Park Cancer InstituteCompletedFallopian Tube Carcinoma | Primary Peritoneal Carcinoma | Stage IIA Ovarian Cancer | Stage IIB Ovarian Cancer | Stage IIC Ovarian Cancer | Stage IIIA Ovarian Cancer | Stage IIIB Ovarian Cancer | Stage IIIC Ovarian Cancer | Stage IV Ovarian Cancer | Stage IA Ovarian Cancer | Stage IB Ovarian Cancer | Stage IC... and other conditionsUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedCancer Survivor | Stage IIIA Ovarian Epithelial Cancer | Stage IIIB Ovarian Epithelial Cancer | Stage IIIC Ovarian Epithelial Cancer | Stage IIA Ovarian Epithelial Cancer | Stage IIB Ovarian Epithelial Cancer | Stage IIC Ovarian Epithelial Cancer | Stage IA Ovarian Epithelial Cancer | Stage IB Ovarian... and other conditionsUnited States
-
Massachusetts General HospitalJohns Hopkins University; M.D. Anderson Cancer Center; National Cancer Institute... and other collaboratorsRecruitingOvarian Neoplasms | Fallopian Tube Neoplasms | Stage III Ovarian Cancer AJCC v8 | Stage IIIA Ovarian Cancer AJCC v8 | Stage IIIA1 Ovarian Cancer AJCC v8 | Stage IIIA2 Ovarian Cancer AJCC v8 | Stage IIIB Ovarian Cancer AJCC v8 | Stage IIIC Ovarian Cancer AJCC v8 | Stage IV Ovarian Cancer AJCC v8 | Stage... and other conditionsUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedOvarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Serous Cystadenocarcinoma | Stage IV Ovarian Germ Cell Tumor | Ovarian Sarcoma | Malignant Ovarian Epithelial Tumor | Ovarian Carcinosarcoma | Ovarian Brenner Tumor | Ovarian Mucinous... and other conditionsUnited States
-
Eve RodlerNot yet recruitingBreast Cancer | Ovarian Cancer | Breast Neoplasm | Breast Carcinoma | Breast Cancer Stage IV | Breast Cancer Stage I | Breast Cancer Stage II | Invasive Breast Cancer | Cancer, Breast | Breast Cancer Stage III | Ovary Cancer | Malignant Tumor of Breast | Ovarian Cancer Stage IIIC | Ovarian Cancer Stage IV | Ovarian Cancer... and other conditionsUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedStage IIA Fallopian Tube Cancer | Stage IIA Ovarian Cancer | Stage IIB Fallopian Tube Cancer | Stage IIB Ovarian Cancer | Stage IIC Fallopian Tube Cancer | Stage IIC Ovarian Cancer | Stage IIIA Fallopian Tube Cancer | Stage IIIA Ovarian Cancer | Stage IIIA Primary Peritoneal Cancer | Stage IIIB Fallopian... and other conditionsUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)RecruitingStage IIIA Ovarian Cancer | Stage IIIB Ovarian Cancer | Stage IIIC Ovarian Cancer | Stage IV Ovarian CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedCaregiver | Stage IIIA Ovarian Cancer | Stage IIIB Ovarian Cancer | Stage IIIC Ovarian Cancer | Stage IV Ovarian CancerUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedStage I Breast Cancer | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage... and other conditionsUnited States
-
University of WashingtonMinnesota Ovarian Cancer AllianceTerminatedStage III Ovarian Cancer AJCC v8 | Stage IIIA Ovarian Cancer AJCC v8 | Stage IIIA1 Ovarian Cancer AJCC v8 | Stage IIIA2 Ovarian Cancer AJCC v8 | Stage IIIB Ovarian Cancer AJCC v8 | Stage IIIC Ovarian Cancer AJCC v8 | Stage IV Ovarian Cancer AJCC v8 | Stage IVA Ovarian Cancer AJCC v8 | Stage IVB Ovarian... and other conditionsUnited States
Clinical Trials on APX005M
-
Apexigen America, Inc.CompletedMelanoma | Cancer | Head and Neck Cancer | NSCLC | Urothelial Carcinoma | MSI-HUnited States
-
Apexigen America, Inc.TerminatedMelanoma | Cancer | Metastatic Melanoma | Melanoma (Skin) | Unresectable Melanoma | Cancer of SkinSpain, Poland
-
Pediatric Brain Tumor ConsortiumNational Cancer Institute (NCI); Solving Kids' Cancer; Ty Louis Campbell Foundation and other collaboratorsActive, not recruitingGlioblastoma Multiforme | Medulloblastoma | High-grade Astrocytoma NOS | CNS Primary Tumor, Nos | Ependymoma, NOS | Diffuse Intrinsic Pontine Gliomas (DIPG)United States
-
James Cleary, MD, PhDLustgarten Foundation; Arcus Biosciences, Inc.RecruitingPancreatic Cancer | Adenocarcinoma of the Pancreas | Squamous Cell Carcinoma of Pancreas | Adenosquamous Carcinoma of the PancreasUnited States
-
Apexigen America, Inc.Bristol-Myers SquibbCompletedMelanoma | Cancer | Metastatic Melanoma | Non Small Cell Lung Cancer Metastatic | Neoplasm of LungUnited States, Spain
-
Yale UniversityBristol-Myers Squibb; National Cancer Institute (NCI); Apexigen America, Inc.Active, not recruitingRenal Cell Carcinoma | Non-small Cell Lung Cancer | Advanced MelanomaUnited States
-
Yale UniversityApexigen America, Inc.RecruitingRenal Cell Carcinoma | Advanced MelanomaUnited States
-
University of Texas Southwestern Medical CenterApexigen America, Inc.Active, not recruitingLocally Advanced Rectal AdenocarcinomaUnited States
-
M.D. Anderson Cancer CenterApexigen America, Inc.; Pyxis OncologyActive, not recruitingMelanomaUnited States
-
Alexander Z. Wei, MDApexigen America, Inc.Active, not recruiting